4.7 Review

Exosomes play roles in sequential processes of tumor metastasis

期刊

INTERNATIONAL JOURNAL OF CANCER
卷 144, 期 7, 页码 1486-1495

出版社

WILEY
DOI: 10.1002/ijc.31774

关键词

exosome; metastasis; tumor microenvironment; pre-metastatic niche; cancer-associated fibroblasts

类别

资金

  1. National Natural Science Foundation of China [81602133, 81773174]

向作者/读者索取更多资源

Overwhelming evidence demonstrates that exosomes, a series of biologically functional small vesicles of endocytic origin carrying a variety of active constituents, especially tumor-derived exosomes, contribute to tumor progression and metastasis. This review focuses on the specific multifaceted roles of exosomes in affecting sequenced four crucial processes of metastasis, through which cancer cells spread from primary to secondary organs and finally form macroscopic metastatic lesions. First, exosomes modulate the primary tumor sites to assist cancer growth and dissemination. In this part, five main biological events are reviewed, including the transfer of oncogenic constituents, the recruitment and activation of fibroblasts, the induction of angiogenesis, immunosuppression and epithelial-mesenchymal transition (EMT) promotion. In Step 2, we list two recently disclosed mechanisms during the organ-specific homing process: the exosomal integrin model and exosomal epidermal growth factor receptor (EGFR)/miR-26/hepatocyte growth factor (HGF) model. Subsequently, Step 3 focuses on the interactions between exosomes and pre-metastatic niche, in which we highlight the specific functions of exosomes in angiogenesis, lymphangiogenesis, immune modulation and metabolic, epigenetic and stromal reprogramming of pre-metastatic niche. Finally, we summarize the mechanisms of exosomes in helping the metastatic circulating tumor cells escape from immunologic surveillance, survive in the blood circulation and proliferate in host organs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles

Keyu Li, Yaliang Lan, Jiabei Wang, Lianxin Liu

TUMOR BIOLOGY (2017)

Article Cell Biology

STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma

Yaliang Lan, Jihua Han, Yan Wang, Jiabei Wang, Guangchao Yang, Keyu Li, Ruipeng Song, Tongsen Zheng, Yingjian Liang, Shangha Pan, Xirui Liu, Mingxi Zhu, Yao Liu, Fanzheng Meng, Manzoor Mohsin, Yifeng Cui, Bo Zhang, Sharma Subash, Lianxin Liu

CELL DEATH & DISEASE (2018)

Article Oncology

Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer

Kenji Fujiwara, May Tun Saung, Hao Jing, Brian Herbst, MacKenzie Zarecki, Stephen Muth, Annie Wu, Elaine Bigelow, Linda Chen, Keyu Li, Neolle Jurcak, Alex B. Blair, Ding Ding, Michael Wichroski, Jordan Blum, Nathan Cheadle, Jennifer Koenitzer, Lei Zheng

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Review Medicine, General & Internal

Primary hepatic myelolipoma: A case report and review of the literature

Ke-Yu Li, Ai-Lin Wei, Ang Li

WORLD JOURNAL OF CLINICAL CASES (2020)

Article Oncology

Successful Neoadjuvant Chemotherapy for Small-Cell Neuroendocrine Carcinoma of the Pancreas: A Case Report

Keyu Li, Jialong Yuan, Yichen Li, Hao Zhang, Xubao Liu, Nengwen Ke

Summary: This study reports a rare case of pancreatic neuroendocrine carcinoma patient who achieved radical surgery after receiving neoadjuvant therapy, providing a new treatment option for similar patients.

FRONTIERS IN ONCOLOGY (2021)

Article Immunology

CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma

Jianxin Wang, May Tun Saung, Keyu Li, Juan Fu, Kenji Fujiwara, Nan Niu, Stephen Muth, Junke Wang, Yao Xu, Noah Rozich, Haley Zlomke, Sophia Chen, Birginia Espinoza, MacKenzie Henderson, Vanessa Funes, Brian Herbst, Ding Ding, Christina Twyman-Saint Victor, Qihong Zhao, Amol Narang, Jin He, Lei Zheng

Summary: This preclinical study demonstrates the potential of CCR2/CCR5 dual-antagonist in counteracting radiation-induced suppressive signals and enhancing the effector T cell pathway. It supports the ongoing clinical trial of combining this therapy with radiation and anti-PD-1 antibody for locally advanced pancreatic cancer.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

Article Oncology

Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses

Tao Xia, Keyu Li, Nan Niu, Yingkuan Shao, Ding Ding, Dwayne L. Thomas, Hao Jing, Kenji Fujiwara, Haijie Hu, Arsen Osipov, Chunhui Yuan, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Jin He, Yiping Mou, Adrian G. Murphy, Lei Zheng

Summary: This study reveals that the densities of Granzyme-B(+)CD8(+) effector T cells, non-exhausted PD-1(-)EOMES(-)CD8(+) T cells, and the PD-L1 status in tumor-associated macrophages are prognostic markers in cholangiocarcinoma. Targeting PD-L1(+) tumor-associated macrophages may be an effective immunotherapy for cholangiocarcinoma.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

Article Oncology

Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model

Pan Li, Noah Rozich, Jianxin Wang, Junke Wang, Yao Xu, Brian Herbst, Raymond Yu, Stephen Muth, Nan Niu, Keyu Li, Vanessa Funes, Jessica Gai, Arsen Osipov, Barish H. Edil, Christopher L. Wolfgang, Ming Lei, Tingbo Liang, Lei Zheng

Summary: This study investigates the potential of a combination therapy involving an anti-IL-8 antibody and an anti-PD-1 antibody for treating pancreatic ductal adenocarcinoma (PDAC). The results show that the combination treatment enhances the antitumor activity and activates the innate immune response in the tumor microenvironment. CD16+ myeloid cells, particularly granulocytes, are identified as the main target of IL-8. These findings provide a basis for further clinical testing of this combination therapy in PDAC treatment and highlight the role of peripherally derived myeloid cells in promoting the antitumor response of T cells.

CANCER LETTERS (2022)

Article Gastroenterology & Hepatology

Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy

Alex B. Blair, Jianxin Wang, John Davelaar, Andrew Baker, Keyu Li, Nan Niu, Junke Wang, Yingkuan Shao, Vanessa Funes, Pan Li, Jonathan A. Pachter, Daniel C. Maneval, Felipe Dezem, Jasmine Plummer, Keith Syson Chan, Jun Gong, Andrew E. Hendifar, Stephen J. Pandol, Richard Burkhart, Yuqing Zhang, Lei Zheng, Arsen Osipov

Summary: This study identifies the synergistic effects of targeting both intracellular and extracellular components within the PDAC stroma, and supports the potential of testing anti-CXCR4 antibody in combination with FAKi as a PDAC treatment strategy.

GASTROENTEROLOGY (2022)

Article Oncology

Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

Keyu Li, Joseph A. Tandurella, Jessica Gai, Qingfeng Zhu, Su Jin Lim, Dwayne L. Thomas II, Tao Xia, Guanglan Mo, Jacob T. Mitchell, Janelle Montagne, Melissa Lyman, Ludmila Danilova, Jacquelyn W. Zimmerman, Benedict Kinny-Koster, Tengyi Zhang, Linda Chen, Alex B. Blair, Thatcher Heumann, Rose Parkinson, Jennifer N. Durham, Amol K. Narang, Robert A. Anders, Christopher L. Wolfgang, Daniel A. Laheru, Jin He, Arsen Osipov, Elizabeth D. Thompson, Hao Wang, Elana J. Fertig, Elizabeth M. Jaffee, Lei Zheng

Summary: Successful immunotherapy for pancreatic ductal adenocarcinoma (PDAC) requires optimization and maintenance of activated effector T cells (Teff). In this study, multi-omic analyses were performed on paired pre- and post-treatment PDAC specimens collected in a neoadjuvant study to uncover sensitivity and resistance mechanisms of a PDAC vaccine (GVAX) combined with nivolumab (anti-PD-1). The results showed that immune-regulatory sites were formed in response to the combination of GVAX and nivolumab. Higher density of tumor-associated neutrophils (TANs) following the combination therapy was associated with poorer overall survival (OS), while increased expression of CD137 on T cells correlated with cytotoxic Teff signatures and increased OS. RNA sequencing analysis revealed that nivolumab altered chemotaxis signaling in CD4+ T cells and CD11b+ neutrophil degranulation, and optimal T cell activation required CD8+ T cell expression of CD137. These findings provide insights into immune pathways regulated by PD-1 in PDAC and could guide the development of more effective therapeutic combinations.

CANCER CELL (2022)

Article Oncology

Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study

Ning Xie, Haoyu Zhou, Li Yu, Shaobing Huang, Can Tian, Keyu Li, Yi Jiang, Zhe-Yu Hu, Quchang Ouyang

Summary: In this study, an AI-based computer-aided system for Ki-67 calculation in breast cancer was developed using the SIFT algorithm. The system improved the accuracy of Ki-67 index calculation and ensured data repeatability among different hospitals and centers.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

Article Multidisciplinary Sciences

A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

Thatcher Heumann, Carol Judkins, Keyu Li, Su Jin Lim, Jessica Hoare, Rose Parkinson, Haihui Cao, Tengyi Zhang, Jessica Gai, Betul Celiker, Qingfeng Zhu, Thomas McPhaul, Jennifer Durham, Katrina Purtell, Rachel Klein, Daniel Laheru, Ana De Jesus-Acosta, Dung T. Le, Amol Narang, Robert Anders, Richard Burkhart, William Burns, Kevin Soares, Christopher Wolfgang, Elizabeth Thompson, Elizabeth Jaffee, Hao Wang, Jin He, Lei Zheng

Summary: A neoadjuvant immunotherapy platform trial using GVAX vaccine with low-dose cyclophosphamide alone, or in combination with nivolumab and urelumab, showed increased intratumoral CD8+ CD137+ cells and potentially improved disease-free and overall survivals in patients with resectable pancreatic adenocarcinoma. This combination therapy demonstrates a promising efficacy signal and warrants further investigation.

NATURE COMMUNICATIONS (2023)

Proceedings Paper Health Care Sciences & Services

Research on 8-unit MIMO antenna of 5G metal frame mobile terminal

Keyu Li, Dongsheng Wu, Lanlan Ping

Summary: An eight-unit MIMO array antenna composed of four ring-slots is proposed for metal-framed mobile terminals in the 5G era. The antenna achieves high isolation and good radiation performance in the LTE band 42 (3.4-3.6 GHz) of 5G communication.

2022 PROGNOSTICS AND HEALTH MANAGEMENT CONFERENCE, PHM-LONDON 2022 (2022)

Article Oncology

Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+T cells

Arsen Osipov, Alex B. Blair, Juliane Liberto, Jianxin Wang, Keyu Li, Brian Herbst, Shiqi Li, Nan Niu, Rufiaat Rashid, Ding Ding, Yanan Liu, Zaiqi Wang, Christopher L. Wolfgang, Richard A. Burkhart, Daniel Laheru, Lei Zheng

Summary: The study demonstrated that FAK inhibition can enhance the antitumor response to radiotherapy in PDAC, with the combination therapy being T cell dependent. FAK inhibition in combination with radiotherapy increased CD8+ T cell infiltration significantly, while inhibiting granulocyte infiltration. This suggests the potential of using FAK inhibitors as radiosensitizers for PDAC and priming the tumor microenvironment for immunotherapy.

CANCER BIOLOGY & MEDICINE (2021)

Article Oncology

Anal cancer screening results from 18-to-34-year-old men who have sex with men living with HIV

Yuxin Liu, Swati Bhardwaj, Keith Sigel, John Winters, Joseph Terlizzi, Michael M. Gaisa

Summary: This study investigated the prevalence and severity of anal HPV disease among MSM LWH under the age of 35, finding a high prevalence of HPV infection and precancer but no cases of invasive anal cancer. This supports the adoption of age-based anal cancer screening for this population.

INTERNATIONAL JOURNAL OF CANCER (2024)